drugset
drugset / Trial / NCT05913024

Immunogenicity and Safety of Enterovirus Type 71 Vaccine,Inactivated(Vero Cells) in Volunteers Aged From 6 to 71 Months

NCT05913024 ↗

Phase 2 Completed 470 enrolled Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The goal of this clinical trial is to evaluate the immunogenicity and safety of Enterovirus Type 71 Vaccine,Inactivated(Vero Cells) in healthy volunteers aged from 6 to 71 months.

Timeline

Start
2021-10-19
Primary completion
2022-10-24
Completion
2022-10-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Enterovirus Type 71 Vaccine Vaccine — —

Indications

No indication recorded.